2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1
2014
Experience with Thoracoscopic Pneumonectomies at a Single Institution
Kim A, Fonseca A, Boffa D, Detterbeck F. Experience with Thoracoscopic Pneumonectomies at a Single Institution. Innovations Technology And Techniques In Cardiothoracic And Vascular Surgery 2014, 9: 82-86. DOI: 10.1177/155698451400900202.Peer-Reviewed Original ResearchVideo-assisted thoracoscopic pneumonectomyThoracoscopic pneumonectomyLung cancerExperienced thoracoscopic surgeonsMetastatic esophageal cancerPrimary lung cancerSingle institution experienceDistant disease recurrenceMultidisciplinary tumor boardKaplan-Meier survivalCompletion pneumonectomyLesser resectionsR0 resectionClinical stagingDisease recurrencePathologic stagingPatient selectionSleeve resectionAtrial fibrillationBronchopleural fistulaClinical parametersComplication profileMedian lengthPreoperative selectionSingle institution